Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Sodium butyrate (NaB) in the gut of animals possesses the potential to modulate lipid metabolism, regulate innate immunity, and protect intestinal health. Accumulating data have supported the important function of metabolites of intestinal microflora (MIM) in nonalcoholic fatty liver disease (NAFLD). This study intended to investigate the role of NaB in NAFLD and its specific mechanism.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Mice were fed a high‐fat diet (HFD) for 16 weeks to establish the NAFLD mouse model. Then, the mice were intragastrically administered MIM (200 µL/day) or NaB (200 mg/kg/day) by gavage for another 8 weeks. Then, the morphology of liver tissues was observed by H&E staining, and the lipid deposition of liver tissues was examined by oil red O staining. The NAFLD cell model was constructed in AML12 cells by 24 h of stimulation with 0.5 mM free fatty acids. After treatment with 10 mM NaB, AML12 cells were transfected with mimic‐miR‐150 or inhibitor‐miR‐150. qRT‐PCR and Western blotting were employed to measure the contents of IL‐1β, IL‐6, and TNF‐α and the expression of miR‐150 and CXCR4 in liver tissues of mice and in AML12 cells. A luciferase reporter assay was applied to verify the binding relationship between miR‐150 and CXCR4.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The H&E and oil red O staining results showed hepatic steatosis in the liver tissues of HFD‐fed mice. There were elevated contents of TG, TC, HDL‐C, LDL‐C, and fasting blood glucose, enhanced activities of ALT and AST, increased homeostatic model assessment of insulin resistance scores and increased inflammatory responses in the serum of HFD‐fed mice. However, intervention with MIM or NaB reversed the above trends, indicating that MIM or NaB intervention relieved hepatic steatosis in mice. HFD‐fed mice had downregulated expression of miR‐150, while the expression level was upregulated after MIM or NaB treatment. NaB attenuated NAFLD progression by regulating miR‐150. MiR‐150 can negatively target CXCR4.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>NaB mitigates HFD‐induced NAFLD in mice by upregulating miR‐150 expression to downregulate CXCR4.</p></section>

Sodium butyrate ameliorates non‐alcoholic fatty liver disease by upregulating miR‐150 to suppress CXCR4 expression

Lactobacillus Casei Yrl577 Ameliorates Markers Of Non-Alcoholic Fatty Liver And Alters Expression Of Genes Within The Intestinal Bile Acid Pathway

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease

Butyrate alleviates alcoholic liver disease-associated inflammation through macrophage regulation and polarization via the HDAC1/miR-155 axis

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice

Butyrate Protects Mice Against Methionine–Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels

MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36

Butyrate Attenuates Hepatic Steatosis Induced by a High-Fat and Fiber-Deficient Diet via the Hepatic GPR41/43-CaMKII/HDAC1-CREB Pathway

[Butyrate increases the monocytic myeloid-derived suppressor cells and promotes the secretion of anti-inflammatory cytokines in mice with alcoholic liver disease]

Biotransformed bear bile powder alleviates diet-induced nonalcoholic fatty liver disease in mice by regulating the gut microbiota and reversing lipid metabolism

Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites

Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway

Chinese Herbal Medicine Formula Shenling Baizhu San Ameliorates High-Fat Diet-Induced NAFLD in Rats by Modulating Hepatic MicroRNA Expression Profiles

Sodium butyrate attenuated diet-induced obesity, insulin resistance and inflammation partly by promoting fat thermogenesis via intro-adipose sympathetic innervation

Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice